Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could ...

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn ...

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad.

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.